Ma José Martinez-Zapata1,2, Lluís Orozco3, Ramon Balius4, Robert Soler3, Alba Bosch5, Gil Rodas6, Lluís Til6,7, Xavier Peirau8, Gerard Urrútia1,2, Ignasi Gich2,9, Xavier Bonfill1,2,9. 1. Iberoamerican Cochrane Centre, IIB Sant Pau, Barcelona, Spain. 2. CIBER of Epidemiology and Public Health, Barcelona, Spain. 3. ITRT, Quirón-Teknon Hospital, Barcelona, Spain. 4. Sport Catalan Council, Generalitat de Catalunya, Barcelona, Spain. 5. Blood and Tissue Bank of Catalonia, Barcelona, Spain. 6. Medical Services, Barcelona Football Club, Barcelona, Spain. 7. High Performance Centre, Health Consortium of Terrassa, Barcelona, Spain. 8. Vithas Montserrat Hospital, Catalunya National Institute of Physical Education, Lleida, Spain. 9. Clinical Epidemiology and Public Health Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: The goals of the treatment of muscle injuries are to shorten the time of healing and to avoid relapses. The aim of this study was to assess the efficacy of autologous platelet-rich plasma (PRP) in the healing of muscle injuries. MATERIALS AND METHODS: A multicentre, randomised, double-blind, parallel, controlled clinical trial was conducted in 71 patients (81.8% males) aged 45.6 (SD=10.0) years with muscle tears in the legs and haematoma. The haematoma was evacuated in all patients. Thirty-three patients were randomised to a single dose of autologous PRP and 38 patients to simulation of PRP administration. The primary end-point was time to complete recovery of muscle injury. Secondary end-points were pain, relapses, ultrasound parameters, and adverse events. The total follow-up per patient was 12 months. RESULTS:Time to complete recovery after the treatment was 31.63 days (SD=15.38) in the PRP group, and 38.43 days (SD=18.58) in the control group (p=0.261). Pain decreased over time in both groups without statistical differences between them. Eight patients relapsed (seven in the control group, and one in the PRP group). There were no adverse effects related to the interventions. DISCUSSION: Autologous PRP did not significantly improve the time to healing compared to that in the control group.
RCT Entities:
BACKGROUND: The goals of the treatment of muscle injuries are to shorten the time of healing and to avoid relapses. The aim of this study was to assess the efficacy of autologous platelet-rich plasma (PRP) in the healing of muscle injuries. MATERIALS AND METHODS: A multicentre, randomised, double-blind, parallel, controlled clinical trial was conducted in 71 patients (81.8% males) aged 45.6 (SD=10.0) years with muscle tears in the legs and haematoma. The haematoma was evacuated in all patients. Thirty-three patients were randomised to a single dose of autologous PRP and 38 patients to simulation of PRP administration. The primary end-point was time to complete recovery of muscle injury. Secondary end-points were pain, relapses, ultrasound parameters, and adverse events. The total follow-up per patient was 12 months. RESULTS: Time to complete recovery after the treatment was 31.63 days (SD=15.38) in the PRP group, and 38.43 days (SD=18.58) in the control group (p=0.261). Pain decreased over time in both groups without statistical differences between them. Eight patients relapsed (seven in the control group, and one in the PRP group). There were no adverse effects related to the interventions. DISCUSSION: Autologous PRP did not significantly improve the time to healing compared to that in the control group.
Authors: João Brito; Robert M Malina; André Seabra; José L Massada; José M Soares; Peter Krustrup; António Rebelo Journal: J Athl Train Date: 2012 Mar-Apr Impact factor: 2.860
Authors: Maria José Martinez-Zapata; Arturo J Martí-Carvajal; Ivan Solà; José Angel Expósito; Ignasi Bolíbar; Luciano Rodríguez; Joan Garcia Journal: Cochrane Database Syst Rev Date: 2012-10-17
Authors: Mohamad Shariff A Hamid; Mohamed Razif Mohamed Ali; Ashril Yusof; John George; Leena Poh Chen Lee Journal: Am J Sports Med Date: 2014-07-29 Impact factor: 6.202
Authors: Alberto Grassi; Francesca Napoli; Iacopo Romandini; Kristian Samuelsson; Stefano Zaffagnini; Christian Candrian; Giuseppe Filardo Journal: Sports Med Date: 2018-04 Impact factor: 11.136
Authors: Gil Rodas; Robert Soler; Ramón Balius; Xavier Alomar; Xavier Peirau; Mercedes Alberca; Ana Sánchez; Javier García Sancho; Clementina Rodellar; Antonio Romero; Lorenzo Masci; Lluís Orozco; Nicola Maffulli Journal: J Orthop Surg Res Date: 2019-12-16 Impact factor: 2.359
Authors: Gian Nicola Bisciotti; Piero Volpi; Maurizio Amato; Giampietro Alberti; Francesco Allegra; Alessandro Aprato; Matteo Artina; Alessio Auci; Corrado Bait; Gian Matteo Bastieri; Luca Balzarini; Andrea Belli; Gianandrea Bellini; Pierfrancesco Bettinsoli; Alessandro Bisciotti; Andrea Bisciotti; Stefano Bona; Lorenzo Brambilla; Marco Bresciani; Michele Buffoli; Filippo Calanna; Gian Luigi Canata; Davide Cardinali; Giulia Carimati; Gabriella Cassaghi; Enrico Cautero; Emanuele Cena; Barbara Corradini; Alessandro Corsini; Cristina D'Agostino; Massimo De Donato; Giacomo Delle Rose; Francesco Di Marzo; Francesco Di Pietto; Drapchind Enrica; Cristiano Eirale; Luigi Febbrari; Paolo Ferrua; Andrea Foglia; Alberto Galbiati; Alberto Gheza; Carlo Giammattei; Francesco Masia; Gianluca Melegati; Biagio Moretti; Lorenzo Moretti; Roberto Niccolai; Antonio Orgiani; Claudio Orizio; Andrea Pantalone; Federica Parra; Paolo Patroni; Maria Teresa Pereira Ruiz; Marzio Perri; Stefano Petrillo; Luca Pulici; Alessandro Quaglia; Luca Ricciotti; Francesco Rosa; Nicola Sasso; Claudio Sprenger; Chiara Tarantola; Fabio Gianpaolo Tenconi; Fabio Tosi; Michele Trainini; Agostino Tucciarone; Ali Yekdah; Zarko Vuckovic; Raul Zini; Karim Chamari Journal: BMJ Open Sport Exerc Med Date: 2018-05-24